• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2022 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

LPBI Group’s Vision

LPBI Group’s Vision is dynamically undated at the following LINKS:

 

2019 Strategic Marketing of LPBI Group’s Intellectual Property: Strength & Markets

https://pharmaceuticalintelligence.com/vision/2019-strategic-marketing-of-lpbi-groups-intellectual-property-strength-markets/

 

TO BE UPDATED on 1/5/2019

https://pharmaceuticalintelligence.com/gama-delta-epsilon-gde-is-a-global-holding-company-absorbing-lpbi/

https://pharmaceuticalintelligence.com/gde-news/

https://pharmaceuticalintelligence.com/calendar/

 

 

 

LPBI Group has Three Enterprise Types and Five Subsidiaries

We are in the Professional Services Sector: e-Scientific Information Creation and Intellectual Property Assets Management:

 

Subsidiary #1: electronic Scientific Media or Scientific Digital Media – LPBI

and

Subsidiary #4: We are intermediaries for Commercialization, Licensing, Sales Outright of US Patents, representing Two inventors in Medical Devices

We are in Research Biotech Businesses

 

Subsidiary #3: R&D in 3D BioPrinting

FUNDING needs: $20Million [If VAR considered: $40Million]

and

Subsidiary #5: R&D in Drug Discovery

FUNDING needs: $20Million

We are in the Financial Transaction Sector (No Securities Traded):

 

Subsidiary #2: Deals, Funding and Partnerships

  • MEDICAL DEVICES
  • Informational PLATFORMS
  • INVENTIONS IN BIOLOGICS

 

 

In Preparation: VB Profile

http://pages.vbprofiles.com/TheMostPopularLists

 

LPBI Group runs by:

Aviva Lev-Ari, PhD, RN – Founder of e-Scientific Media Enterprise (2012) and the LPBI Group (2016)

CORE VALUES

Leadership quality of our Team members:

Straightforward and Transparent, Honest and Trustworthy, Ethical and Principled, Authentic, Focused, Determined, Realistic, Decisive and Action-oriented, Accountable, Fair and Open-minded, Knowledgeable and Experienced, Consistent and Dependable, Confident and Optimistic, Insightful, discerning, Passionate, Empathetic and Selfless, Flexible, Humble, Courageous, Reciprocity, Hardworking.

Since LPBI Group’s IP is unencumbered, commercialization of US Patents is rendered to Funding rather than to litigation. Our Platform is accessible only to members of the Team in the Three Enterprise Type consisting of five subsidiaries that follow our Core values: 

  • deep Expertise  
  • shake of hand instead of 21 page contracts
  • venture wellbeing comes first, personnel wellbeing is derived only from a healthy venture
  • full transparency with the Team and with Investors
  • loyalty to Management, to each Team member and daily adherence to Business Etiquette 
  • Team Playing is key — pushing back is not acceptable

STRATEGIC PLAN for LPBI Group (Draft)

http://pharmaceuticalintelligence.com/gama-delta-epsilon-gde-is-a-global-holding-company-absorbing-lpbi/2016-strategic-plan-for-gde-enterprises/

 

What’s Part of LPBI Group?

MATERIAL BELOW THIS POINT IS UNDER CONSTRUCTION

HIGHLIGHTS

Subsidiary #1: Leaders in Pharmaceutical Business Intelligence

Scientific Digital Media

LPBI

  • Open Access Online Scientific Journal – IP by Our Team

http://pharmaceuticalintelligence.com

  • e-Books: WE ARE ON AMAZON.COM – IP by Our Team

http://www.amazon.com/dp/B00DINFFYC

http://www.amazon.com/dp/B018Q5MCN8

http://www.amazon.com/dp/B018PNHJ84

http://www.amazon.com/dp/B018DHBUO6

http://www.amazon.com/dp/B013RVYR2K

http://www.amazon.com/dp/B012BB0ZF0

http://www.amazon.com/dp/B019UM909A 

http://www.amazon.com/dp/B019VH97LU

  • Biotech Conferences – Real Time Press Coverage of Biotech and Medicine Conferences

IP by Aviva and Dr. Williams.

By 12/2016 will be a candidate to consider M&A

Subsidiary #2: Deals, Funding & Partnerships

DFP

Funding Early Stage Biotech: IP by others

  • Biologics or
  • Medical Devices.

Average investment needed per venture $10Million and above

Subsidiary #3: Medical 3D BioPrinting

M3DP

Team of 15 – IP by Our Team

  • Aviva manages R&D by the Team creating IP for a Pipeline of Medical Applications using 3D BioPrinting in two specialty departments: 
  1. R&D in Tissue Engineering, Gene Therapy: Stem Cells and Gene Editing and Drug dosing and printing
  2. R&D in BioMEMS, Programmable Sensors and Medical Devices
  • Gerard manages development of VARS of BioPrinters and BioInks

Funding needs: $20Million

Subsidiary #4: U.S. and Int’l Patents – Commercialization, Licensing and Sales  

USPat

IP by Patent Holders

  • Funding needed to commercialize,
  • Partnerships to license
  • Buyers for Sales of IP of Two Team members:

(a) to “corporate accounts”

(b) to “IP and Technology Patents Fund Managers”

Subsidiary #5: Joint Ventures for Intellectual Property Development

JVIP

SBH & M3DP (same Team as Subsidiary #3) – IP by Our Team

  • Aviva manages R&D conducted by these two organizations created by a collaborative effort, creation of a pipeline of product concepts 
  • Seeking Funding of  $20Milllion

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email this to a friend (Opens in new window)

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 1,979 other subscribers

  • Recent Posts

    • Omecamtiv mecarbil – A study examined efficacy and tolerability in Heart Failure patients with SBP ≤100 mmHg enrolled in GALACTIC-HF May 23, 2022
    • Sperm epigenetic clock and pregnancy outcomes May 14, 2022
    • Lessons on the Frontier of Gene & Cell Therapy – The Disruptive Dozen 12 #GCT Breakthroughs that are revolutionizing Healthcare May 9, 2022
    • Relevance of Twitter.com forthcoming Payment System for Scientific Content Promotion and Monetization May 9, 2022
    • Tweets at #WMIF2022 by @pharma_BI & @AVIVA1950 and all Retweets of these Tweets – 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON May 7, 2022
    • Data Science: Step by Step – A Resource for LPBI Group’s One-Year Internship in IT, IS, DS May 7, 2022
    • 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON • IN-PERSON May 1, 2022
    • We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022 April 25, 2022
    • The durability of T cells versus the triggered of high levels of antibodies: Rationale for the development of T cells focused vaccines   April 22, 2022
    • The Framingham Study: Across 6 Decades, Cardiovascular Disease Among Middle-Aged Adults – mean life expectancy increased and the RLR of ASCVD decreased. Effective primary prevention efforts and better screening increased. April 22, 2022
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 Rosalind Codrington, PhD
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 vaishnavee24
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
%d bloggers like this: